BusinessPreclinical Data Showing Synergy of Biothera Pharmaceuticals’ Imprime PGG and a CD40 Agonist in a Pancreatic Cancer Model Presented at Keystone SymposiaBy Nasdaq OMXMar 26, 2018, 2:00 PM UTC
BusinessBiothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC
BusinessBiothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC
BusinessBiothera Pharmaceuticals to Discuss Imprime PGG Combination Therapy with Checkpoint Inhibitors at Molecular Medicine Tri-Conference 2017By Nasdaq OMXFeb 15, 2017, 3:26 PM UTC
BusinessBiothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck CancerBy Nasdaq OMXDec 5, 2016, 2:30 PM UTC
